The International Cancer Benchmarking Partnership (ICBP) is a unique and innovative collaboration that brings together clinicians, policymakers, researchers and data experts across the world. It aims to measure international variation in cancer survival, incidence and mortality, as well as identify factors that might be driving these differences.
The ICBP produces high quality research to help identify best international practice, and generate insights needed for policy and practice change. This will help to enable optimisation of cancer services and improvement of outcomes for cancer patients.
The ICBP is an international multidisciplinary collaboration to help improve outcomes for patients.
ICBP’s Phase 3 builds on past insights to deepen our understanding through new and innovative research and focus on turning this into real-world change.
An overview of research and activities currently underway in the Transition Phase
Summary of ICBP’s Phase 2 research findings and health system factors explaining international cancer survival variation.
Summary of ICBP’s Phase 1 research findings and reasons behind international cancer survival variation.
Explore the ICBP SurvMark-2 data
If you have any views or comments about the partnership, we would like to hear from you.
Join the conversation and follow the ICBP on LinkedIn to stay informed on the latest updates from the partnership.
Join the conversation on LinkedIn
